CytomX Therapeutics (CTMX) Common Equity (2014 - 2026)
CytomX Therapeutics (CTMX) posted Common Equity of $319.9 million for Q1 2026, up 223.15% on a QoQ basis from $99.0 million in Q4 2025, and up 1177.27% year-over-year from $25.0 million in Q1 2025.
CytomX Therapeutics (CTMX) Common Equity (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Common Equity history runs 13 years deep, the most recent figure standing at $319.9 million for Q1 2026.
- Quarterly Common Equity rose 1177.27% year-over-year to $319.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319.9 million (up 1177.27% YoY) and the FY2025 annual result came in at $99.0 million, up 21812.28% from the prior year.
- Common Equity was $319.9 million for Q1 2026 at CytomX Therapeutics, up from $99.0 million in the prior quarter.
- Across five years, Common Equity topped out at $319.9 million in Q1 2026 and bottomed at -$86.6 million in Q1 2023.
- A 5-year average of $3.7 million and a median of -$31.2 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity slumped 18582.14% — and 2025, when it jumped 21812.28%.
- CytomX Therapeutics' Common Equity stood at -$85.8 million in 2022, then soared by 44.67% to -$47.4 million in 2023, then soared by 99.04% to -$456000.0 in 2024, then soared by 21812.28% to $99.0 million in 2025, then soared by 223.15% to $319.9 million in 2026.
- Business Quant data shows CTMX's Common Equity at $319.9 million in Q1 2026, $99.0 million in Q4 2025, and $107.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 251.12 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -98.34 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.76 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.36 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 19.36 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 31.42 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.79 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.50 Bn |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | 319.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 319.94 Mn |
| Dec 31, 2025 | 99.01 Mn |
| Sep 30, 2025 | 107.39 Mn |
| Jun 30, 2025 | 119.91 Mn |
| Mar 31, 2025 | 25.05 Mn |
| Dec 31, 2024 | -456,000.00 |
| Sep 30, 2024 | -23.45 Mn |
| Jun 30, 2024 | -31.23 Mn |
| Mar 31, 2024 | -31.68 Mn |
| Dec 31, 2023 | -47.45 Mn |
| Sep 30, 2023 | -51.24 Mn |
| Jun 30, 2023 | -85.03 Mn |
| Mar 31, 2023 | -86.64 Mn |
| Dec 31, 2022 | -85.75 Mn |
| Sep 30, 2022 | -80.54 Mn |
| Jun 30, 2022 | -54.54 Mn |
| Mar 31, 2022 | -29.74 Mn |
| Dec 31, 2021 | -459,000.00 |
| Sep 30, 2021 | 30.43 Mn |
| Jun 30, 2021 | 58.11 Mn |